The Global HIV Vaccine Enterprise
is an alliance of independent organizations around the world dedicated to accelerating the development of a preventive HIV vaccine by:
- Shared scientific plan: Implementing a strategic plan for HIV vaccine research that spans vaccine discovery, product development and manufacturing, and clinical trials
- Increased resources: Mobilizing significant new funding to achieve the scientific plan
- Greater collaboration: Promoting more efficient, faster ways for researchers to share successes and failures and avoid duplication of efforts
The Enterprise Approach
Enterprise Satellite Session at AIDS 2008 Conference in Mexico City – August 3, 2008
Please join us on Sunday, August 3 at the AIDS 2008 Conference in Mexico City for a roundtable discussion with leaders in HIV vaccine research to discuss an important issue facing the field: how to attract and retain the next generation of investigators. Please see the flyer for more information.
Enterprise Satellite Session Flyer
NIAID Announces that PAVE 100 Vaccine Trial Will Not Move Forward – July 17, 2008
On July 17, 2008, the National Institute of Allergies and Infectious Diseases (NIAID) announced that it will not move forward with the PAVE 100 HIV vaccine clinical trial as originally proposed. NIAID will instead consider a smaller, more focused trial with a smaller number of volunteers, and will restrict its analysis to the effect of the vaccine candidate on HIV viral load. Please see the below links for a statement from Enterprise Executive Director Alan Bernstein, the NIAID press release, and a New York Times story about the announcement quoting Dr. Antony Fauci of NIAID and Dr. Bernstein.
Message from Alan Bernstein
As he concludes his first few months as Executive Director of the Enterprise, Dr. Bernstein would like to update everyone on Enterprise activities, reflect upon recent developments in the field, and identify some initial priorities for the organization over the coming year. Click the link below for his update.
Message from Alan Bernstein
Enterprise Statement to Commemorate HIV Vaccine Awareness Day - May 18, 2008
May 18 marks HIV Vaccine Awareness Day – a day to recognize the need for a safe and effective HIV vaccine and to express gratitude to the thousands of volunteers, communities, and health professionals across the globe working to make this dream a reality. With dedication, renewed commitment and global collaboration, HIV/AIDS will be defeated. While no one can put a timeline on success, the world looks forward to a time when this day will commemorate the discovery of a successful HIV vaccine.
Click here to read full Enterprise statement
Editorial by Dr. Bernstein featured in May 9, 2008 edition of Science
“Later this month, researchers will gather at the Institut Pasteur in Paris to mark the quarter century since human immunodeficiency virus (HIV) was discovered as the cause of acquired immunodeficiency syndrome (AIDS). Since then, over 60 million people have been infected with the virus and over 25 million people have died. These numbers make the results of two "proof of concept" vaccine efficacy trials--the STEP and Phambili trials--extremely disappointing. Indeed, these results have raised questions about whether investments in HIV vaccine research are misplaced and whether a vaccine is even achievable. Those views are misguided. The failure of candidate vaccines or drugs is to be expected. More than ever, investigations in humans are essential to explore concepts, test hypotheses, and delineate the human immune response to HIV immunogens.”
Read full text of Dr Bernstein’s Science editorial here
More News from the Enterprise
Scientific Strategic Plan
The Enterprise's scientific strategic plan for accelerating HIV vaccine research was published in the February 2005 issue of Public Library of Science (PLoS) — Medicine